Diabetes drugs 'pose heart risk'
Two drugs commonly prescribed to treat type 2 diabetes double the risk of heart failure, a study of data on more than 78,000 patients suggests. More than 1.5 million prescriptions for rosiglitazone and pioglitazone were issued in England alone last year. The researchers, led by the University of East Anglia, suggest fluid retention caused by the drugs may be to blame. Writing in the journal Diabetes Care, they call for a rethink on the drugs by the regulatory authorities.